
MGTX Stock Forecast & Price Target
MGTX Analyst Ratings
Bulls say
MeiraGTx Holdings PLC is positioning itself for sustained growth with an extended financial runway into 2027, bolstered by the anticipated closing of the Hologen deal. The company is demonstrating significant advancements in its clinical pipeline, particularly in ophthalmology, with all patients in recent trials showing improvements in visual acuity and overall patient outcomes. Additionally, the upcoming Biologics License Application (BLA) filing in 2026, supported by promising Phase II results, underscores the company’s commitment to developing effective and safe gene therapies, enhancing its long-term financial prospects.
Bears say
MeiraGTx Holdings PLC is facing a significant risk related to the potential inability to secure regulatory approval for its pipeline products, which could lead to downward revisions in projections and negatively affect financial performance. The company's reported net loss of $148 million, translating to an EPS of ($2.12), was worse than the estimated ($2.27), indicating ongoing financial challenges. Additionally, complexities in the regulatory path and frequent manufacturing setbacks associated with its gene therapy products further heighten the uncertainty surrounding the company's financial outlook.
This aggregate rating is based on analysts' research of MeiraGTx Holdings plc and is not a guaranteed prediction by Public.com or investment advice.
MGTX Analyst Forecast & Price Prediction
Start investing in MGTX
Order type
Buy in
Order amount
Est. shares
0 shares